Loading...
Based on the provided data, Aehr Test Systems (AEHR) is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts such as growth in AI-related spending and strong market demand recovery, the company's recent financial performance, insider selling, and lowered analyst price targets suggest caution. The stock may be better suited for more experienced investors or those with a higher risk tolerance.
The technical indicators show mixed signals. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock closed lower (-4.05%) in the regular market, and the key resistance level at R1 (40.681) is close to the current price, indicating limited short-term upside.

Optimism about achieving 94% growth in
Initial production order for AI processor testing systems.
CEO's projection of $60M-$80M bookings for the second half of the fiscal year.
Growth in AI-related spending and stabilization in the EV market.
Insiders are selling shares, with a 252.27% increase in selling over the last month.
Revenue dropped significantly (-26.53% YoY) in the latest quarter.
Gross margin declined sharply (-35.85% YoY).
Analyst Craig-Hallum lowered the price target to $21 from $24, citing lower-than-expected results and guidance.
In Q2 2026, revenue dropped to $9.88M (-26.53% YoY), while net income improved to -$3.23M (+214.20% YoY). EPS increased to -0.11 (+266.67% YoY), but gross margin declined to 25.75% (-35.85% YoY). The financials show mixed results, with growth in profitability metrics but a decline in revenue and margins.
Analysts have mixed views. Craig-Hallum lowered the price target to $21 and maintained a Hold rating due to weak guidance. However, Lake Street initiated coverage with a Buy rating and a $29 price target, citing the company's unique positioning in next-gen semiconductor testing and a significant market opportunity in AI processors and HPC devices.